Articles From: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results to Aetna Adds Loyola University Health System to Its Network


2013/3/21
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results Canada NewsWire All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012 .
Sign-up for Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results investment picks
2013/3/21
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012 .
Sign-up for Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results investment picks
2013/5/1
Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013 Canada NewsWire QUEBEC CITY, May 1, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2013 financial and operating results after market close on Tuesday, May 7, 2013 .
Sign-up for Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013 investment picks
2013/5/1
QUEBEC CITY , May 1, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2013 financial and operating results after market close on Tuesday, May 7, 2013 .
Sign-up for Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013 investment picks
2013/3/12
QUEBEC CITY , March 12, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2012 financial and operating results on Thursday, March 21, 2013 , after market close.
Sign-up for Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013 investment picks
2013/3/12
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013 Canada NewsWire QUEBEC CITY, March 12, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2012 financial and operating results on Thursday, March 21, 2013 , after market close.
Sign-up for Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013 investment picks
2013/3/11
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation Canada NewsWire QUEBEC CITY, March 11, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade ® ) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
Sign-up for Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation investment picks
2013/3/11
QUEBEC CITY , March 11, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade ® ) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
Sign-up for Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation investment picks
2013/5/15
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co.
Sign-up for Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto investment picks
2013/5/15
QUÉBEC CITY, May 15, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the Company's Senior Vice President and CFO, Dennis Turpin CPA CA, will be presenting a corporate overview at the Bloom Burton & Co.
Sign-up for Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto investment picks
2013/3/13
QUÉBEC CITY, March 13, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel , PhD, will be presenting a corporate overview at the Roth 25 th Annual OC Growth Stock Conference on Tuesday, March 19, 2013 , at 9:30 am (Pacific), in Track 6: Salon 5-Pink of the Ritz Carlton hotel in Dana Point, California .
Sign-up for Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference investment picks
2013/3/13
Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference Canada NewsWire QUÉBEC CITY, March 13, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel, PhD, will be presenting a corporate overview at the Roth 25 th Annual OC Growth Stock Conference on Tuesday, March 19, 2013 , at 9:30 am (Pacific), in Track 6: Salon 5-Pink of the Ritz Carlton hotel in Dana Point , California.
Sign-up for Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference investment picks
2013/4/3
Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting Canada NewsWire SOURCE: AETERNA ZENTARIS INC.
Sign-up for Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting investment picks
2013/4/3
QUÉBEC CITY, April 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Babette Aicher , PhD, Director of Preclinical Development, will be making a poster presentation on updated proof-of-concept results for Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft models, at the upcoming American Association for Cancer Research ("AACR") annual meeting, which will be held April 6-10, 2013 , in Washington D.C. The study is funded through a grant from the German Ministry of Education and Research.
Sign-up for Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting investment picks
2013/6/3
QUÉBEC CITY, June 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin (AEZS-108), demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer.
Sign-up for Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO investment picks
2013/6/3
Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO Canada NewsWire QUÉBEC CITY, June 3, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin (AEZS-108), demonstrated the compound's promising anti-tumor activity in heavily pre-treated men with castration- and taxane-resistant prostate cancer.
Sign-up for Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO investment picks
2013/2/20
QUÉBEC CITY, Feb.
Sign-up for Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer investment picks
2013/5/23
QUÉBEC CITY, May 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the following posters will be presented on AEZS-108, the Company's lead oncology compound, at the upcoming American Society of Clinical Oncology ("ASCO") annual meeting, which will be held May 31 to June 4, 2013 , in Chicago .
Sign-up for Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting investment picks
2013/5/23
Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting Canada NewsWire Abstract # 5062:   "A Phase 1 Dose Escalating Trial of AEZS-108 in Taxane- and Castration-Resistant Prostate Cancer" , J.
Sign-up for Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting investment picks
2013/4/18
SAN DIEGO , April 18, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) , disclosed that a poster presentation entitled: "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens," is being presented today at the International Society of Extracellular Vesicles  (ISEV) 2013 conference being held in Boston , MA.
Sign-up for Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013 investment picks
2013/1/29
SAN DIEGO , Jan.
Sign-up for Aethlon Medical Discloses CEO Interview investment picks
2013/2/11
Company invites individual and institutional investors to log-on to view presentation NEW YORK , Feb.
Sign-up for Aethlon Medical, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com investment picks
2013/5/7
HOUSTON, May 7, 2013 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) a leading supplier of power delivery solutions for the global energy industry, today announced its 2013 first quarter results.
Sign-up for AETI Announces 395% Increase in First Quarter Net Income investment picks
2013/3/5
HOUSTON, March 5, 2013 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) , a leading supplier of power delivery solutions for the global energy industry, today announced its 2012 fourth quarter and annual results.
Sign-up for AETI Announces Quarterly Financial Growth, Improved Annual Results investment picks
2013/6/6
HOUSTON, June 6, 2013 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) , a leading provider of power delivery solutions for the global energy industry, announced today that Chief Executive Officer Charles Dauber will present at Sidoti & Company's Semi-Annual Micro-Cap Conference at the Grand Hyatt New York Hotel in New York City on Friday, June 7, 2013.
Sign-up for AETI CEO to Present at Sidoti & Company's Micro-Cap Conference investment picks
2013/5/6
HOUSTON, May 6, 2013 (GLOBE NEWSWIRE) -- American Electric Technologies, Inc. (Nasdaq:AETI) , a leading supplier of power delivery solutions for the global energy industry, today announced it will begin offering arc-resistant switchgear allowing end users to create safer work environments, comply with electrical regulations for the workplace, and better protect lives and assets.
Sign-up for AETI Extends Product Portfolio to Include Arc-Resistant Switchgear investment picks
2013/2/26
HOUSTON, Feb.
Sign-up for AETI Names Troy Coker Director of Sales for Upstream Oil and Gas Market investment picks
2013/4/30
Aetna Inc.'s (AET) first-quarter earnings fell 4.1%, partly due to integration and other charges, while the health insurer's revenue and membership rolls increased.
Sign-up for Aetna 1st-Quarter Net Falls 4.1% on Charges; Raises Year View investment picks
2013/2/4
Aetna (NYSE: AET ) and Loyola University Health System announced today that Loyola will soon join Aetna’s network.
Sign-up for Aetna Adds Loyola University Health System to Its Network investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results to Aetna Adds Loyola University Health System to Its Network
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity